Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bioverativ Fills Gap In Pipeline With $400m True North Buy

May 23 2017

• By Mandy Jackson

RedBloodCellsOnWhite_1200x675

Related Content

iPierian raises $30m to target tau, spin out complement program

Sep 04 2013

Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A

May 23 2017

Bioverativ Hits The Street Ready To Expand In Blood Disorders

Jan 26 2017

INTERVIEW: Biogen's Danos on why now is gene therapy's time

Feb 09 2015

True North Therapeutics Inc.

Feb 20 2014

1Q EARNINGS: BMS sees sales slide, plans nivolumab rolling BLA

Apr 30 2014

Patient Registries Prove Value As Drug Development Tools

Apr 19 2016

VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth

Nov 01 2016

BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis

Jan 10 2014

Related Companies

Sanofi

Biogen, Inc.

True North Therapeutics, Inc.

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Xenetic Biosciences, Inc.

Bayer AG

Novo Nordisk A/S

Sangamo Therapeutics, Inc.

iPierian, Inc.

Bristol Myers Squibb Company

Additional Topics

Deals Business Strategies Rare Diseases Commercial Blood & Coagulation Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window